Equities

Vivani Medical Inc

Vivani Medical Inc

Actions
  • Price (EUR)1.20
  • Today's Change-0.04 / -3.23%
  • Shares traded--
  • 1 Year change+21.21%
  • Beta--
Data delayed at least 15 minutes, as of Oct 31 2024 20:40 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vivani Medical, Inc. is a biopharmaceutical company developing novel, ultra-long-acting drug implants. Leveraging its NanoPortal platform, the Company develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Its lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight individuals. Its pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight management in obese and overweight individuals. NPM-119 refers to its Type II diabetes development program. OKV-119 is an exenatide implant that is under development for metabolic diseases in cats, including for the treatment of obesity and diabetes. Its segments include Biopharm Division and Neurostimulation Division.

  • Revenue in USD (TTM)0.00
  • Net income in USD-24.20m
  • Incorporated2023
  • Employees44.00
  • Location
    Vivani Medical Inc1350 S. Loop RoadALAMEDA 94502United StatesUSA
  • Phone+1 (415) 506-8462
  • Websitehttps://vivani.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.